Thrombectomy for Distal and Medium Vessel Occlusions: The Limits of Intervention

Following the success of thrombectomy for proximal large vessel occlusions (ICA, M1), attention turned to more distal occlusions—M2, M3, and beyond. Medium vessel occlusions (MeVO) account for an estimated 25–40% of acute ischemic strokes and can cause significant disability. The hypothesis seemed logical: if removing clot works for M1, it should work for M2 and M3. However, three recent randomized trials have challenged this assumption, consistently showing no benefit—and potential harm—from thrombectomy in distal occlusions.

Defining Medium and Distal Vessel Occlusions

Terminology in this field can be confusing. Medium vessel occlusions (MeVO) generally refer to occlusions of:

• M2 segment: MCA branches after the bifurcation (proximal vs. distal M2)
• M3/M4 segments: More distal MCA branches
• A2/A3 segments: Anterior cerebral artery branches
• P1/P2/P3 segments: Posterior cerebral artery branches

These occlusions were largely excluded from the landmark thrombectomy trials (MR CLEAN, DAWN, DEFUSE 3), which focused on ICA and M1 occlusions. Observational studies suggested thrombectomy was technically feasible in M2 occlusions, leading to equipoise and the need for randomized data.

The MeVO Trials: Consistently Neutral Results

DUSK (2024)

DUSK was a prospective registry comparing EVT versus medical management in 321 patients with isolated distal medium vessel occlusions (M3/M4, A2/A3, P1/P2).

• No significant difference in mRS ordinal shift
• No difference in mRS 0–2 or mRS 0–1 rates
• No difference in 90-day mortality

Clinical Pearl: DUSK established clinical equipoise for the most distal occlusions, suggesting that the natural history with medical therapy alone is relatively favorable.

DISTAL (2025)

DISTAL randomized 543 patients with medium distal vessel occlusions (non-dominant M2, M3, M4, A1–A3, P1–P3) to EVT versus best medical treatment within 6 hours (or 6–24 hours with perfusion mismatch).

• 90-day median mRS: 2 in both groups
• mRS 0–1 at 90 days: 37.5% (BMT) vs. 34.7% (EVT)
• Symptomatic ICH: 2.6% (BMT) vs. 5.9% (EVT)
• Embolism to new territory: 6.3% with EVT
• Arterial perforation: 3% with EVT
• 90-day mortality: 14% (BMT) vs. 15.5% (EVT)

Clinical Pearl: DISTAL demonstrated that EVT provides no functional benefit and is associated with significantly higher sICH and procedural complications including embolization to new vascular territories.

ESCAPE-MEVO (2025)

ESCAPE-MEVO evaluated EVT (using Solitaire stent retriever as first-line) versus medical treatment in patients with MeVO (proximal M2, distal M2, M3, A2/A3, P2/P3) within 12 hours of onset.

• 90-day median mRS: 2 (medical) vs. 2 (EVT)
• mRS 0–1 at 90 days: 43.1% (medical) vs. 41.6% (EVT)
• mRS 0–2 at 90 days: 58.8% (medical) vs. 54.1% (EVT)
• Symptomatic ICH: 2.2% (medical) vs. 5.4% (EVT)
• 90-day mortality: 8.4% (medical) vs. 13.3% (EVT)
• Barthel Index >95: 64.6% (medical) vs. 53.5% (EVT)

Clinical Pearl: ESCAPE-MEVO not only showed no benefit but trended toward worse outcomes with EVT—higher mortality, higher sICH, and lower functional independence. The authors noted that stent retrievers may not be the optimal technique for smaller vessels.

Why Did Thrombectomy Fail in Distal Occlusions?

Favorable Natural History

Unlike proximal LVO where medical therapy alone yields poor outcomes (mRS 0–2 in ~20%), distal occlusions have a much better natural history. In ESCAPE-MEVO, nearly 60% of medically treated patients achieved functional independence. When the control arm does well, demonstrating benefit from intervention becomes difficult.

Technical Limitations

Current thrombectomy devices—stent retrievers and large-bore aspiration catheters—were designed for the M1 segment and ICA. In smaller, more tortuous distal vessels:

• Device-to-vessel size mismatch increases perforation risk
• Navigation is more challenging
• Clot fragmentation and distal embolization are more common
• Vessel wall injury may be more consequential

Procedural Complications

The trials consistently showed higher complication rates with EVT:

• Symptomatic ICH approximately doubled (5–6% vs. 2–3%)
• Embolization to new vascular territories (6% in DISTAL)
• Arterial perforation (3% in DISTAL)
• These complications may offset any potential benefit from recanalization

Patient Selection

Patients with distal occlusions often have lower baseline NIHSS scores. The potential for improvement is smaller, while procedural risks remain. The risk-benefit calculation differs fundamentally from proximal LVO.

Future Directions

The negative MeVO trials do not close the door entirely on distal thrombectomy. Several areas warrant further investigation:

• Aspiration-first techniques: Smaller-profile aspiration catheters may be safer than stent retrievers in distal vessels
• Novel devices: Purpose-built devices for medium vessels are in development
• Patient selection: Subgroups with larger clot burden or poor collaterals may still benefit
• IV thrombolysis optimization: Tenecteplase may achieve adequate recanalization in many MeVO cases

Conclusion

The MeVO trials represent an important lesson in stroke intervention: not all occlusions benefit from thrombectomy. Despite technical feasibility, EVT for distal and medium vessel occlusions does not improve outcomes and may cause harm. Current evidence supports medical management as the standard of care for MeVO, with thrombectomy reserved for highly selected cases or clinical trials. Future research should focus on developing safer techniques and identifying subpopulations who may benefit.